Lopinavir+ Ritonavir- Secondary outcomes of study show some benefits

https://www.nejm.org/doi/full/10.1056/NEJMoa2001282

Cao et al. carried out a randomized, controlled, open-label trial for lopinavir–ritonavir
(ritonavir helps to stabilize lopinavir) in 199 hospitalized patients with severe COVID-19, of whom 99 were assigned to the treatment group, and 100 received the standard of care. The authors found no benefit of lopinavir–ritonavir time to clinical improvement beyond the standard of care, although lopinavir–ritonavir was found to have benefit for some secondary endpoints, the safety of the treatment was confirmed, and future trials will verify the results.

Tags: